Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01159028
Recruitment Status : Active, not recruiting
First Posted : July 9, 2010
Last Update Posted : January 18, 2018
Information provided by (Responsible Party):
Bio-Path Holdings, Inc.